Abstract library

227 results for "Non-Medical Prescribing".
#2195 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)
Introduction: The number of people living with cancer in the UK continues to rise with increased demands on specialist cancer care services. NET incidence and prevalence increases alongside this demand. NETs remain a rare cancer with specialist needs. The clinical nurse specialist (CNS) is ideally placed to support these patients. Oncology clinics are increasingly pressured, the need to think of innovative ways of reducing strain whilst maintaining and enhancing the patients experience is important. To address this we set up a nurse-led SACT NMP clinic alongside the oncology clinic to improve patient experience and reduce oncologist clinic review.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Philippa Davies
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#3057 Epidemiological Features of Patients with NeuroEndocrine Neoplasms (NENs): Preliminary Results of an Observational Study by the Hellenic Society of Medical Oncology (HeSMO)
Introduction: NENs are rare tumors and can grow in almost all tissues. Regardless histological, molecular and imaging characteristics that are indicative of the primary origin, a significant percentage remain of unknown primary.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, MSc, PhD Nikolaos Tsoukalas
#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids
Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Others
Presenting Author: MASTER DEGREE Katiuscia Benfini
#3077 Insights into the Practice Patterns, Challenges and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients in the Community
Introduction: Management of NET patients often involves a multidisciplinary approach,requiring collaboration between referring oncologists,surgeons,endocrinologists locally and NET specialty centers (NSC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yelamanchili Radhika
Authors: Radhika Y, Chan D, Thawer A, Lo D, ...
#275 The Use of Guar Gum in the Medical Management of Hyperinsulinaemic Hypoglycaemia
Introduction: Medical therapy, including guar gum, is frequently required in the management of patients with endogenous hyperinsulinaemic hypoglycaemia (e.g. insulinoma), especially if surgery is not appropriate.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
Authors: Carroll R W, Todd J F, ...
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#1171 Clinical Characteristics and Treatment Outcome of Six Advanced G3 Well-Differentiated Neuroendocrine Tumors
Introduction: According to 2010 WHO grading system, all neuroendocrine neoplasms were divided into G1/G2/G3 based on Ki-67 and mitotic count. However, differentiation was also very important for the biological behavior and treatment strategy.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Ru Jia
Authors: Jia R, Chen H E, Chen Y L, Ge F J, ...
#1491 Do Medical Oncology Services Receive More Patients with Neuroendocrine Tumors? Assessment of This Tendency and Reflections About Its Aid Complexity
Introduction: Neuroendocrine tumors meant a change in the clinical practice, multidisciplinary approach (MA) is the gold standard today.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Carmen Salvador
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump